If a patient presents with microcytic anemia due to chronic kidney disease, what compensatory change would be least effective in improving erythropoiesis?

💡 Explanation

Erythropoietin (EPO) stimulates red blood cell production; in kidney disease, EPO production is impaired. Administering recombinant EPO directly addresses the deficiency, therefore this is more effective, rather than simply supplementing iron or folate when the issue is EPO deficiency. The others provide substrates but not stimulation.

• Why does excessive fibrinolysis increase the risk of hemorrhage following tissue plasminogen activator (tPA) administration for stroke?
• If a drug inhibits pancreatic beta cell glucokinase in a patient with Type 2 diabetes already exhibiting insulin resistance, which consequence follows?
• Why does maladaptive vasodilation occur during septic shock, compromising thermoregulation?
• If antibiotic treatment shifts from targeting planktonic bacteria to a biofilm, which consequence follows?
• If a patient chronically takes exogenous glucocorticoids to suppress inflammation, which consequence follows due to negative feedback?
• During intense exercise, alveolar PO2 remains relatively stable despite increased ventilation and O2 consumption. Which mechanism explains why alveolar PO2 doesn't drop significantly?